Revisiting clinical trials on glycemic control and cardiovascular risk

The most relevant clinical trials, assessing the role of glycemic control in reducing cardiovascular risk, are examined. The UKPDS was the first to address this issue. More recent trials (ACCORD, ADVANCE and VADT) are controversial and evidences did not support that strict glycemic control (reflecte...

Descripción completa

Detalles Bibliográficos
Autor principal: Ferreira, Sandra Roberta Gouvea
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761296/
https://www.ncbi.nlm.nih.gov/pubmed/19825201
http://dx.doi.org/10.1186/1758-5996-1-12
_version_ 1782172824558895104
author Ferreira, Sandra Roberta Gouvea
author_facet Ferreira, Sandra Roberta Gouvea
author_sort Ferreira, Sandra Roberta Gouvea
collection PubMed
description The most relevant clinical trials, assessing the role of glycemic control in reducing cardiovascular risk, are examined. The UKPDS was the first to address this issue. More recent trials (ACCORD, ADVANCE and VADT) are controversial and evidences did not support that strict glycemic control (reflected by normal glycated hemoglobin) exclusively is sufficient to reduce cardiovascular risk in complicated individuals with long-term type 2 diabetes mellitus. Some possible reasons for controversies are included.
format Text
id pubmed-2761296
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27612962009-10-14 Revisiting clinical trials on glycemic control and cardiovascular risk Ferreira, Sandra Roberta Gouvea Diabetol Metab Syndr Commentary The most relevant clinical trials, assessing the role of glycemic control in reducing cardiovascular risk, are examined. The UKPDS was the first to address this issue. More recent trials (ACCORD, ADVANCE and VADT) are controversial and evidences did not support that strict glycemic control (reflected by normal glycated hemoglobin) exclusively is sufficient to reduce cardiovascular risk in complicated individuals with long-term type 2 diabetes mellitus. Some possible reasons for controversies are included. BioMed Central 2009-09-28 /pmc/articles/PMC2761296/ /pubmed/19825201 http://dx.doi.org/10.1186/1758-5996-1-12 Text en Copyright © 2009 Ferreira; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Ferreira, Sandra Roberta Gouvea
Revisiting clinical trials on glycemic control and cardiovascular risk
title Revisiting clinical trials on glycemic control and cardiovascular risk
title_full Revisiting clinical trials on glycemic control and cardiovascular risk
title_fullStr Revisiting clinical trials on glycemic control and cardiovascular risk
title_full_unstemmed Revisiting clinical trials on glycemic control and cardiovascular risk
title_short Revisiting clinical trials on glycemic control and cardiovascular risk
title_sort revisiting clinical trials on glycemic control and cardiovascular risk
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761296/
https://www.ncbi.nlm.nih.gov/pubmed/19825201
http://dx.doi.org/10.1186/1758-5996-1-12
work_keys_str_mv AT ferreirasandrarobertagouvea revisitingclinicaltrialsonglycemiccontrolandcardiovascularrisk

Ejemplares similares